22.418 articles found

USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE

WOLF HANS UWE, WILHELM CHRISTOPH.

· 2006-06-26

IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT

NANGIA Avinash, JACOB Jules, YEH James, MOSLEMY Peyman, VERMA Daya D., HASWANI Dinesh K., SHAKED Ze'ev.

· 2006-06-23

Novel therapeutic extracts and molecules for degenerative conditions

PATELL VILLO M.

· 2006-06-23

Dosage forms for movement disorder treatment

NANGIA AVINASH, JACOB JULES, YEH JAMES, MOSLEMY PEYMAN, VERMA DAYA D, HASWANI DINESH K, SHAKED ZE'EV.

· 2006-06-23

Dosage forms for movement disorder treatment

NANGIA AVINASH, JACOB JULES, MOSLEMY PEYMAN, VERMA DAYA D, HASWANI DINESH K.

· 2006-06-23

Dosage forms for movement disorder treatment

NANGIA AVINASH, JACOB JULES, YEH JAMES, MOSLEMY PEYMAN, VERMA DAYA D, HASWANI DINESH K, SHAKED ZE'EV.

· 2006-06-23

IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT

SHAKED ZE EV, HASWANI DINESH K, NANGIA AVINASH, JACOB JULES, VERMA DAYA D, MOSLEMY PEYMAN, YEH JAMES.

· 2006-06-23

Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease.

Koike H, Ishida A, Shimamura M, Mizuno S, Nakamura T, Ogihara T, Kaneda Y, Morishita R.

Gene Ther · 2006-06-22

DOI: 10.1038/sj.gt.3302810PMID: 16791285

Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.

Knyihár-Csillik E, Chadaide Z, Mihály A, Krisztin-Péva B, Fenyo R, Vécsei L.

Acta Neuropathol · 2006-06-21

DOI: 10.1007/s00401-006-0086-4PMID: 16788821

USE OF ROTIGOTINE FOR TREATMENT OR PREVENTION OF DOPAMINERGIC NEURONE LOSS

SCHELLER DIETER, DRESSEN FRANK.

· 2006-06-20

Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets.

Ramassamy C.

Eur J Pharmacol · 2006-06-17

DOI: 10.1016/j.ejphar.2006.06.025PMID: 16904103

A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

Forsayeth JR, Eberling JL, Sanftner LM, Zhen Z, Pivirotto P, Bringas J, Cunningham J, Bankiewicz KS.

Mol Ther · 2006-06-16

DOI: 10.1016/j.ymthe.2006.04.008PMID: 16781894